CKBR-12® Induces Rapid Amelioration and Elimination of Motor and Non-Motor Symptoms in Parkinson’s disease Patients
Susanne Cappendijk van Engelen, PhD, MBA1, Juan Morales, MD2, Robert Rand, SemperClarus Consulting, LLC, Tallahassee, Florida, United States; Louis Marks , Genesis Parkinson’s Institute, Genesis Ibogaine Institute , Rosarito, Baja California; Phytostan Enterprises, Inc. Montreal, Quebec, Canada. What was done is a randomized, double-blind, placebo-controlled clinical trial involving participants diagnosed with Parkinson’s disease to evaluate the safety, tolerability, and preliminary efficacy of ibogaine. Early in the course and during the further progression of Parkinson’s disease (PD) patients experience a plethora of non-motor symptoms (NMS). In contrast to the well-recognized and well-accepted PD motor symptoms, such as involuntary shaking and muscle stiffness, numerous physicians and/or caretakers might still not realize the impact of the NMS on their patient’s Health-Related Quality of Life (HRQOL). A recent performed survey study by Genesis Treatment Center (end of 2014) demonstrated that for PD patients the array of NMS, such as sleep disorders, increased anxiety, uncertainty about the risk of developing dementia, urinary incontinence and motor symptoms are significant contributors to a decreased HRQOL score.
Patient-Reported Outcome tools related to evaluate the HRQOL were employed to analyze data collected from the study in which the natural health product CKBR-12® was utilized in an experimental protocol in the treatment of NMS and motor and non motor dysfunction symptoms of PD. Using a holistic patient-driven view of care, we demonstrated an acute and longer-term interruption, a tremendous amelioration or total elimination of both NMS and motor symptoms of PD, leading to an overall improvement of patient HRQOL. No return of any symptoms were noted, as well as a possible halt to the progression of PD. Our unexpected, promising and previously unreported results gave rise to the filing of a US and PCT provisional patent, Rapid Method for Interrupting Motor and Non-Motor Symptoms of Parkinson’s Disease, prompting calls for expanded patient access to CKBR-12® trials.
Conference (New York Academy Of Sciences: Non-Motor Symptoms: Unraveling the “Invisible” Face of Parkinson’s disease**:
A randomized, double-blind, placebo-controlled clinical trial involving participants diagnosed with Parkinson’s disease to evaluate the safety, tolerability, and preliminary efficacy of ibogaine is now necessary.. The primary objective is to further examine the effect of CKBR-12® on the NMS in PD
:•Phase 1/11 study: safety and tolerability
•Randomized-start study (RSD)The secondary long-term objective is to examine whether CKBR-12® is a DMA for PD: Futility study There is proof that the active ingredient of CKBR-12® (12-Methoxyibogamine) stimulates the Glial Cell Derived Neurotrophic Factor (GDNF) and as such stimulates the production of dopamine and could act as a neuroprotective and a neurorestorative agent. Our main long-term objective is to examine whether CKBR-12® can be considered as a Disease Modifying or a halt the progression Agent for Parkinson’s disease, or a cure. Have CKBR-12® approved for use in the United States of America as well.